$52.23
0.46% yesterday
NYSE, Aug 12, 10:00 pm CET

Haemonetics Corporation Stock price

$52.23
-24.43 31.87% 1M
-9.08 14.81% 6M
-25.85 33.11% YTD
-22.43 30.04% 1Y
-22.97 30.55% 3Y
-27.74 34.69% 5Y
+13.28 34.10% 10Y
+30.75 143.16% 20Y
NYSE, Closing price Tue, Aug 12 2025
-0.24 0.46%

Key metrics

Basic
Market capitalization
$2.5b
Enterprise Value
$3.4b
Net debt
$918.0m
Cash
$306.8m
Shares outstanding
48.2m
Valuation (TTM | estimate)
P/E
15.5 | 10.7
P/S
1.9 | 1.9
EV/Sales
2.5 | 2.6
EV/FCF
28.4
P/B
3.1
Financial Health
Equity Ratio
33.5%
Return on Equity
20.4%
ROCE
12.6%
ROIC
9.7%
Debt/Equity
1.5
Financials (TTM | estimate)
Revenue
$1.4b | $1.3b
EBITDA
$283.9m | $441.2m
EBIT
$235.6m | $347.7m
Net Income
$167.7m | $237.0m
Free Cash Flow
$121.3m
Growth (TTM | estimate)
Revenue
4.0% | -2.8%
EBITDA
20.4% | 50.3%
EBIT
15.6% | 41.8%
Net Income
42.7% | 41.3%
Free Cash Flow
5.1%
Margin (TTM | estimate)
Gross
55.9%
EBITDA
20.9% | 33.4%
EBIT
17.3%
Net
12.3% | 17.9%
Free Cash Flow
8.9%
More
EPS
$3.4
FCF per Share
$2.5
Short interest
9.7%
Employees
4k
Rev per Employee
$370.0k
Show more

Is Haemonetics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Haemonetics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Haemonetics Corporation forecast:

13x Buy
87%
1x Hold
7%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Haemonetics Corporation forecast:

Buy
87%
Hold
7%
Sell
7%

Financial data from Haemonetics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,361 1,361
4% 4%
100%
- Direct Costs 601 601
1% 1%
44%
760 760
8% 8%
56%
- Selling and Administrative Expenses 411 411
0% 0%
30%
- Research and Development Expense 63 63
16% 16%
5%
284 284
20% 20%
21%
- Depreciation and Amortization 48 48
51% 51%
4%
EBIT (Operating Income) EBIT 236 236
16% 16%
17%
Net Profit 168 168
43% 43%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Haemonetics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Haemonetics Corporation Stock News

Positive
Seeking Alpha
one day ago
Haemonetics Corporation remains a high-quality blood-management franchise with strong TEG and plasma software moats, but recent growth has paused due to portfolio shifts and competition. Q1 FY2026 results beat expectations on margins and cash flow, but headline revenue declined due to deliberate exits and one-time factors boosting growth. HAE valuation is compelling at ~11x forward EPS and ~8x ...
Neutral
Seeking Alpha
3 days ago
Haemonetics Corporation (NYSE:HAE ) Q1 2026 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christopher A. Simon - CEO, President & Director James C.
Neutral
The Motley Fool
6 days ago
Haemonetics (HAE) Q1 Revenue Falls 4%
More Haemonetics Corporation News

Company Profile

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.

Head office United States
CEO Christopher Simon
Employees 3,657
Founded 1971
Website www.haemonetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today